Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/09/2013 | 03:06pm CEST

Development Progress Builds on Encouraging Clinical Data in Idiopathic Pulmonary Fibrosis (IPF)

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is advancing PRM-151, a recombinant form of an endogenous human protein that offers the potential to prevent and potentially reverse fibrosis. The Phase 2 clinical study of PRM-151 in patients with myelofibrosis, which is expected to complete in 2014, expands Promedior's clinical focus beyond IPF to myelofibrosis, another serious, life-limiting orphan disease with significant unmet medical need.

"Advancing the clinical development of PRM-151, our lead product candidate, into clinical studies in myelofibrosis patients is a significant milestone for Promedior," said Elizabeth G. Trehu, MD, FACP, Promedior's Chief Medical Officer. "We are optimistic that data from this study, combined with the encouraging data in IPF, will demonstrate that PRM-151's novel mechanism of action is applicable to a wide range of fibrotic diseases."

Promedior's clinical development program in myelofibrosis with PRM-151 builds upon a randomized, placebo-controlled clinical study in patients with IPF, in which PRM-151 was generally safe and well?tolerated and resulted in a mean improvement in Forced Vital Capacity (FVC) at 8 weeks after dosing for only two weeks, whereas patients receiving placebo had a decline in FVC. In addition, PRM-151 has demonstrated broad anti-fibrotic activity in multiple industry standard preclinical models of fibrotic disease, including pulmonary fibrosis, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration.

"Despite the success of JAK inhibitors, there is still a critical need for new therapeutic approaches for patients with myelofibrosis. With its unique mechanism of action that offers the potential to prevent and reverse fibrosis, Promedior's PRM-151 has the potential to become a first-in-class disease-modifying treatment for this debilitating disease," said Srdan Verstovsek, MD, PhD, Professor and Section Chief for Myeloproliferative Neoplasms, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and principal investigator for the study.

This clinical trial is a multi-center, two stage, adaptive design Phase 2 study to determine the efficacy and safety of PRM-151 as a single agent or added to a stable dose of ruxolitinib in patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF). The primary endpoint is response rate according to the International Working Group- Myeloproliferative Neoplasms Research and Treatment criteria, a comprehensive assessment tool designed by an international group of experts to objectively measure the effectiveness of treatments for MF¹. Approximately 24 patients are expected to enroll in the first stage of the study, with up to 80 additional patients in the second stage. For additional details about this clinical trial, please visit www.clinicaltrials.gov.

About Myelofibrosis

Myelofibrosis (MF), a type of myeloproliferative neoplasm, is a serious, life-limiting cancer that is characterized by fibrosis of the bone marrow. Replacement of the bone marrow by scar tissue prevents the normal production of blood cells, leading to anemia, fatigue, and increased risk of bleeding and infection. Production of blood cells shifts to the spleen and liver (extramedullary hematopoiesis), which become enlarged, causing severe discomfort, inability to eat, and weakness. Symptomatic myelofibrosis affects approximately 18,000 people per year in the US, with a median age of 61-66.². The only potentially curative treatment is allogeneic bone marrow transplant, which results in reversal of fibrosis and all symptoms, but is a realistic option for only a small number of patients. Other currently available therapies address the symptoms, but have minimal if any impact on the underlying fibrosis.

About PRM-151

PRM-151, Promedior's lead product candidate, is a recombinant form of an endogenous human protein, Pentraxin-2 (PTX-2), that is specifically active at the site of tissue damage. PRM-151 is an agonist that acts as a macrophage differentiation factor to prevent and potentially reverse fibrosis. PRM-151 has shown broad anti-fibrotic activity in multiple preclinical models of fibrotic disease, including pulmonary fibrosis, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration.

Phase 1a and 1b clinical studies in healthy subjects and IPF patients have demonstrated that PRM-151 was safe and well tolerated. Additionally, a Phase 1b study in patients with IPF showed encouraging results in exploratory efficacy endpoints, which were presented in an oral session at the 2013 Annual Meeting of the American Thoracic Society³.

About Promedior

Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon Pentraxin-2, an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, potentially preventing and reversing fibrosis.

Promedior has successfully advanced its lead therapeutic candidate in human clinical trials, and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis. Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team. For additional information about Promedior, please visit www.promedior.com.

 
1. Tefferi, A., et al, "Revised Response Criteria for Myelofibrosis: International Working Group- Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report," Blood 122(8): 1395-8; 2013.
 
2. Mehta, J., Wang, H., Iqbal, S. U., Mesa, R., "Epidemiology of myeloproliferative neoplasms in the United States", Leukemia & Lymphoma, Early Online: 1-6, 2013.
 
3.

Van Den Blink, B. et al., "A Phase I Study Of PRM-151 In Patients With Idiopathic Pulmonary Fibrosis", American Thoracic Society 2013 Annual Meeting, May 2013. Read More: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5707

 

Media:
The Yates Network
Kathryn Morris, 845-635-9828
[email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
03:50a PLANET FITNESS : Rochester Police believe they know who beat woman
03:49a GRUPO BIMBO B DE C : Promotes innovative entrepreneurship
03:49a NPS NATIONAL PARK SERVICE : National Park Service Announces Fire Restrictions
03:47a CIN7 : Releases One-Click Integration with Walmart Marketplace
03:44a BEST BUY : Von Miller Talks Football, Tech and Geekdom
03:39a NOC NATIONAL OIL : Chairman inspects the conditions of the workers and talks to them while breaking Ramadan fast in a group Iftar in Al Sharara Oil Field
03:35a MAZDA MOTOR : Colliding cars cause dramatic Kennewick Ave. rollover
03:34a CITY OF BELMONT CA : Manager's Weekly Update
03:33a Ritz-Carlton, Riyadh hosts orphans from ‘INSAN’ for Iftar
03:20a REPORT : Walmart won't make rival bid for Whole Foods
Latest news
Advertisement
Hot News 
18.96%IMAGINATION TECHNOLOGIES : U.K. Chip Designer Puts Itself on Block -- WSJ
-5.33%GLOBAL LOGISTIC PROPERTIES : Says It Remains in Talks With Shortlisted Bidders
0.54%Accenture unloads $1.6 billion in pension liabilities to AIG, MassMutual
-1.65%ANTHEM : Agrees to $115 Million Settlement of Data Breach Lawsuit
-1.94%FTSE haunted by uncertainty one year after Brexit vote
Most Read News
06:21p Europe faces Herculean challenge to develop new fighter jet
06:33p SEAWORLD ENTERTAINMENT : subpoenaed on disclosures about 'Blackfish' impact, trading
06:49p JUST IN : This retailer plans to open in The Gardens Mall
08:14p Under pressure, Western tech firms bow to Russian demands to share cyber secrets
07:54p CISCO : Securing Your Data in the Transformation to Digital
Most recommended articles
08:53p Oil's drop could leave a stain on earnings
08:20pDJOil Prices Up as Bigger Producers Stick to Cuts
08:14p Under pressure, Western tech firms bow to Russian demands to share cyber secrets
07:48p Even with Whole Foods, Amazon would need many more warehouses to reshape grocery delivery
06:33p SEAWORLD ENTERTAINMENT : subpoenaed on disclosures about 'Blackfish' impact, trading